Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Breast Cancer Research and Treatment|June 18, 2017
A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)Lori J Goldstein, Fengmin Zhao, Molin Wang, et al.
Journal of the National Cancer Institute|July 30, 2026
A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab, and pertuzumab in hormone receptor (HR)-positive, HER2-positive metastatic breast cancer (ASPIRE)Rima Patel, Maryann Kwa, Paula Klein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2025
A Phase II Randomized Study of Paclitaxel alone or combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor Positive Breast Cancer: the BRACELET-01/PrE0113 studyAmy S Clark, Fengmin Zhao, Paula Klein, et al.
Breast Cancer Research and Treatment|August 16, 2025
Randomized phase II comparison of single-agent carboplatin versus combination of carboplatin and everolimus for advanced triple negative breast cancerRima Patel, Jami Fukui, Paula Klein, et al.
Neuro-Oncology Practice|May 14, 2026
End-of-life challenges in neuro-oncological patient care: A survey from the Junge Neuroonkologische ArbeitsgemeinschaftLazaros Lazaridis, Niklas Benedikt Pepper, Paula Klein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2018
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102Noah Kornblum, Fengmin Zhao, Judith Manola, et al.
NPJ Breast Cancer|July 20, 2017
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trialKerin Adelson, Bhuvaneswari Ramaswamy, Joseph A Sparano, et al.
Pageof 3